TScan Therapeutics Pauses Clinical Trial and Cuts Workforce by 75% Due to Capital Constraints

Filing content

The company is pausing enrollment in its heme malignancy clinical trial and reducing its workforce by approximately 75% to prioritize its solid tumor program. It also received a notice of non-compliance with Nasdaq's minimum bid price rule.